High content screen microscopy analysis of Aβ1–42-induced neurite outgrowth reduction in rat primary cortical neurons: Neuroprotective effects of α7 neuronal nicotinic acetylcholine receptor ligands

beta-Amyloid peptide 1-42 (A beta(1-42)) is generated from amyloid precursor protein (APP) and associated with neurodegeneration in Alzheimer's disease (AD). A beta(1-42) has been shown to be cytotoxic when incubated with cultured neurons. However, APP transgenic mice over-expressing A beta(1-42) do not show substantial loss of neurons, despite deficits in learning and memory. It is thus emerging that A beta(1-42)-induced memory deficits may involve subtler neuronal alternations leading to synaptic deficits, prior to frank neurodegeneration in AD brains. In this study, high content screen (HCS) microscopy, an advanced high-throughput cellular image processing and analysis technique, was utilized in establishing an in vitro model of A beta(1-42)-induced neurotoxicity utilizing rat neonatal primary cortical cells. Neurite outgrowth was found to be significantly reduced by A beta(1-42) (300 nM to 30 microM), but not by the scrambled control peptide control, in a time- and concentration-dependent manner. In contrast, no reduction in the total number of neurons was observed. The A beta(1-42)-induced reduction of neurite outgrowth was attenuated by the NMDA receptor antagonist memantine and the alpha 7 nicotinic acetylcholine receptor (nAChR) selective agonist PNU-282987. Interestingly, the alpha 7 nAChR antagonist methyllycaconitine also significantly prevented reduction in A beta(1-42)-induced neurite outgrowth. The observed neuroprotective effects could arise either from interference of A beta(1-42) interactions with alpha 7 nAChRs or by modification of receptor-mediated signaling pathways. Our studies demonstrate that reduction of neurite outgrowth may serve as a model representing A beta(1-42)-mediated neuritic and synaptic toxicity, which, in combination of HCS, provides a high-throughput cell-based assay that can be used to evaluate compounds with neuroprotective properties in neurons.

[1]  A. Nordberg,et al.  Effect of Subchronic Treatment of Memantine, Galantamine, and Nicotine in the Brain of Tg2576 (APPswe) Transgenic Mice , 2006, Journal of Pharmacology and Experimental Therapeutics.

[2]  D. Mash,et al.  Characterization of l‐[3H]Nicotine Binding in Human Cerebral Cortex: Comparison Between Alzheimer's Disease and the Normal , 1986, Journal of neurochemistry.

[3]  R. Kayed,et al.  Soluble Aβ oligomers ultrastructurally localize to cell processes and might be related to synaptic dysfunction in Alzheimer's disease brain , 2005, Brain Research.

[4]  R. Papke,et al.  Neuroprotective and memory-related actions of novel alpha-7 nicotinic agents with different mixed agonist/antagonist properties. , 1998, The Journal of pharmacology and experimental therapeutics.

[5]  M. Rowan,et al.  The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention. , 2005, Biochemical Society transactions.

[6]  S. Shaw,et al.  Janus Kinase 2, an Early Target of α7 Nicotinic Acetylcholine Receptor-mediated Neuroprotection against Aβ-(1–42) Amyloid* , 2002, The Journal of Biological Chemistry.

[7]  T. Morgan,et al.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[8]  J. Buccafusco,et al.  Relationship between the increased cell surface α7 nicotinic receptor expression and neuroprotection induced by several nicotinic receptor agonists , 2001, Journal of neuroscience research.

[9]  M. Gallagher,et al.  A specific amyloid-β protein assembly in the brain impairs memory , 2006, Nature.

[10]  G. Wilcock,et al.  The cholinergic hypothesis of Alzheimer’s disease: a review of progress , 1999, Journal of neurology, neurosurgery, and psychiatry.

[11]  C. Lemere,et al.  Amyloid-beta immunotherapy for the prevention and treatment of Alzheimer disease: lessons from mice, monkeys, and humans. , 2006, Rejuvenation research.

[12]  Edward D. Levin,et al.  Nicotinic and muscarinic interactions and choice accuracy in the radial-arm maze , 1991, Brain Research Bulletin.

[13]  D. Selkoe Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease. , 2002, The Journal of clinical investigation.

[14]  P. Lee,et al.  Smoking and Alzheimer's disease: a review of the epidemiological evidence. , 1994, Neuroepidemiology.

[15]  M. Albert,et al.  Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. , 1989, JAMA.

[16]  R. Papke,et al.  Characterization of the neuroprotective and toxic effects of α7 nicotinic receptor activation in PC12 cells , 1999, Brain Research.

[17]  J. Miguel-Hidalgo,et al.  Neuroprotection by memantine against neurodegeneration induced by β-amyloid(1–40) , 2002, Brain Research.

[18]  W. K. Cullen,et al.  Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.

[19]  L. M. Espinoza-Fonseca,et al.  Molecular docking of four β-amyloid1–42 fragments on the α7 nicotinic receptor: delineating the binding site of the Aβ peptides , 2004 .

[20]  D. Westaway,et al.  Interactions between β-amyloid and central cholinergic neurons: implications for Alzheimer’s disease , 2004 .

[21]  R. Papke,et al.  Multiple calcium channels and kinases mediate α7 nicotinic receptor neuroprotection in PC12 cells , 2005, Journal of neurochemistry.

[22]  A. Nordberg,et al.  Protein and mRNA levels of nicotinic receptors in brain of tobacco using controls and patients with Alzheimer's disease , 2003, Neuroscience.

[23]  N. C. D. Fiebre,et al.  The α7 nicotinic acetylcholine receptor-selective antagonist, methyllycaconitine, partially protects against β-amyloid1–42 toxicity in primary neuron-enriched cultures , 2004, Brain Research.

[24]  Yun Wang,et al.  Mediation of BMP7 neuroprotection by MAPK and PKC IN rat primary cortical cultures , 2004, Brain Research.

[25]  Dominic M. Walsh,et al.  Deciphering the Molecular Basis of Memory Failure in Alzheimer's Disease , 2004, Neuron.

[26]  R. Malinow,et al.  APP Processing and Synaptic Function , 2003, Neuron.

[27]  A. Nordberg,et al.  Reduced levels of Aβ 40 and Aβ 42 in brains of smoking controls and Alzheimer's patients , 2004, Neurobiology of Disease.

[28]  L. Mucke,et al.  SIRT1 Protects against Microglia-dependent Amyloid-β Toxicity through Inhibiting NF-κB Signaling* , 2005, Journal of Biological Chemistry.

[29]  John M. Lee,et al.  Pharmacological Drug Treatment of Alzheimer Disease: The Cholinergic Hypothesis Revisited , 1998, Journal of neuropathology and experimental neurology.

[30]  D. Price,et al.  Mutant genes in familial Alzheimer's disease and transgenic models. , 1998, Annual review of neuroscience.

[31]  S. Shimohama,et al.  Nicotinic receptor stimulation protects neurons against β‐amyloid toxicity , 1997 .

[32]  P. A. Peterson,et al.  β-Amyloid1–42 Binds to α7 Nicotinic Acetylcholine Receptor with High Affinity , 2000, The Journal of Biological Chemistry.

[33]  C. Finch,et al.  Synaptic Targeting by Alzheimer's-Related Amyloid β Oligomers , 2004, The Journal of Neuroscience.

[34]  J. Corwin,et al.  Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer’s disease , 1999, Psychopharmacology.

[35]  Mark Bowlby,et al.  Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Kang Hu,et al.  High-Level Neuronal Expression of Aβ1–42 in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation , 2000, The Journal of Neuroscience.

[37]  S. Wonnacott,et al.  Nicotine activates the extracellular signal‐regulated kinase 1/2 via the α7 nicotinic acetylcholine receptor and protein kinase A, in SH‐SY5Y cells and hippocampal neurones , 2002, Journal of neurochemistry.

[38]  P. Keller,et al.  Globular amyloid β‐peptide1−42 oligomer − a homogenous and stable neuropathological protein in Alzheimer's disease , 2005 .

[39]  A. Nordberg,et al.  Expression of nicotinic receptors on primary cultures of rat astrocytes and up-regulation of the α7, α4 and β2 subunits in response to nanomolar concentrations of the β-amyloid peptide1–42 , 2005, Neurochemistry International.

[40]  D Bertrand,et al.  Nicotinic acetylcholine receptors as drug targets. , 2004, Current drug targets. CNS and neurological disorders.

[41]  S. Gauthier,et al.  Comparative Alterations of Nicotinic and Muscarinic Binding Sites in Alzheimer's and Parkinson's Diseases , 1992, Journal of neurochemistry.

[42]  C. Hama,et al.  Microglial α7 nicotinic acetylcholine receptors drive a phospholipase C/IP3 pathway and modulate the cell activation toward a neuroprotective role , 2006, Journal of neuroscience research.

[43]  Brett Chromy,et al.  Soluble oligomers of β amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus , 2002, Brain Research.

[44]  D. Donnelly-roberts,et al.  In vitro neuroprotective properties of the novel cholinergic channel activator (ChCA), ABT-418 , 1996, Brain Research.

[45]  H. Ogura,et al.  Protective effect of donepezil against Aβ(1-40) neurotoxicity in rat septal neurons , 2005, Brain Research.

[46]  J. R. James,et al.  Genetic and environmental aspects of the role of nicotinic receptors in neurodegenerative disorders: Emphasis on Alzheimer's disease and Parkinson's disease , 1995, Behavior genetics.

[47]  D. L. Taylor,et al.  Advances in high content screening for drug discovery. , 2003, Assay and drug development technologies.

[48]  E. Wong,et al.  Discovery and structure-activity relationship of quinuclidine benzamides as agonists of alpha7 nicotinic acetylcholine receptors. , 2005, Journal of medicinal chemistry.

[49]  D. Small,et al.  Alpha7-nicotinic acetylcholine receptors mediate an Abeta(1-42)-induced increase in the level of acetylcholinesterase in primary cortical neurones. , 2004, Journal of neurochemistry.

[50]  D. Murphy,et al.  Neuroendocrine, physiologic, and behavioral responses following intravenous nicotine in nonsmoking healthy volunteers and in patients with alzheimer's disease , 1990, Psychoneuroendocrinology.